Garri Zmudze
Co-Founding Partner & Managing Partner @ LongeVC
Garri Zmudze is a seed investor at LongeVC focused on Biotechnology and SaaS. Garri is a seasoned business angel with an extensive track record in tech business and an early investor in science-intensive ventures, such as Insilico Medicine, Basepaws, Deep Longevity. Prior to founding LongeVC, he co-founded Longenesis — a medical technology startup company working towards providing a technological bridge between Healthcareinstitutions and the BioTech industry with an aim to help identify and unlock the hidden value of biomedical data to accelerate the novel drug and treatment discovery and provide better help to those in need. In 2021, Garri became Director of the Board at Longevity Science Foundation — a Swiss and USA based non-profit organisation advancing human longevity by funding research and development of medical technologies to extend the healthy human lifespan.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Garri Zmudze invests in
Stages Garri Zmudze invests in
Countries Garri Zmudze invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $300k–$2.2M
Investment Focus
Industry
- Biotechnology 3 (33%)
- SaaS 2 (22%)
- Software 2 (22%)
- Health Care 2 (22%)
- Artificial Intelligence 2 (22%)
Stage
- Seed 5 (56%)
- Pre-Seed 2 (22%)
- Venture - Series Unknown 2 (22%)
Country
- United States 5 (56%)
- Hong Kong 2 (22%)
- Estonia 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| PickMyBrain.com is an AI-powered Library of People's Knowledge that functions like a search engine. All the answers are sourced from the videos recorded by real people directly on the PickMyBrain platform or their external materials, like YouTube interviews, articles or books. Every member can build personal AI, personalize communicationstyle, monetize access to AI or to 1:1 personal questions to real people behind these AI's. | $2.1M / Pre-Seed / Apr 01, 2026 | ||
| DOG PPL is a park, café, bar, and lounge, all in one. | Venture - Series Unknown / Jul 17, 2024 | ||
| Profi is an operating platform for scaling professional services businesses - coaching, consulting, and training service providers. The Profi operating system covers professional services firms' end-to-end lifecycle and workflows from their first sale to the full scale. Profi focuses on streamlining the full-cycle business operations andservice delivery process, including automating and enhancing client onboarding, payments, content and service delivery, multi-provider workflow support, reporting, analytics, roles & permissions, CRM, and more. It allows professional services firms to consolidate their tech stack, reduce costs, unlock growth, and service their clients in one system. | Seed / Mar 06, 2024 | ||
| Haut.AI is an innovative SaaS product that automates the collection of high-quality skin data and helps skincare brands create interactive product recommendations on e-commerce platforms. Haut.AI's B2B SaaS tool is available as an API and SDK for AI skin analysis. This product facilitates R&D, provides essential tools for building skinanalysis apps and allows brands to develop a better understanding of their clients' needs. | $2.2M / Seed / Nov 15, 2023 | ||
| Freedom Biosciences is a biotechnology platform developing next-generation psychedelic therapeutics. | Venture - Series Unknown / Feb 14, 2023 | ||
| Longenesis is a blockchain-based personal data marketplace. | $1.2M / Seed / Jun 25, 2021 | ||
| Basepaws is a pet genetics company. The first company of its kind, Basepaws created a direct-to-consumer feline DNA test, focusing on delivering breed and trait information and actionable health insights. Each test reveals the genetic breakdown of the cat, with results that explain breed composition and health markers. As more owners add to thegrowing database, future reports will be able to link results with potential diseases and nutrition needs. We work closely with pet owners, veterinarians, breeders, shelters and pet nutrition companies, and will use genomic data in a variety of fields including pet nutrition and therapeutics. Our products are built on proprietary cost-saving sequencing technology which combines whole genome sequencing with the specificity of amplicon approaches. Our tests are available in various online and offline channels, and the database built will be used in creation of additional products and services, such as personalized pet food and pet health coaching. | Seed / Mar 03, 2018 | ||
| Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | $300K / Seed / Apr 16, 2014 | ||
| Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and,unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI. | Pre-Seed / Mar 02, 2014 |
Co-Investors
About LongeVC
LongeVC was created to support early-stage biotech and longevity-focused founders on their way to gain industrial momentum, raise capital, and grow to become the shapers of tomorrow's biotech industry.
LongeVC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Garri Zmudze
Co-Founding Partner & Managing Partner
|
|||
Ilya Suharenko
Managing Partner and Co-Founder
|
|||
Sergey Jakimov
Co-Founder and Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Garri Zmudze invest in?
Garri Zmudze invests primarily in Biotechnology, SaaS and Software startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Garri Zmudze's check size?
Garri Zmudze typically joins rounds of $300k–$2.2M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Garri Zmudze participates in.
How do I contact Garri Zmudze?
Public channels for Garri Zmudze include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Garri Zmudze last invest?
The most recent investment recorded for Garri Zmudze closed in Apr 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
